What does this research mean for the field?

First-line treatment with zongertinib demonstrates sustained efficacy and predominantly low-grade adverse events in patients with advanced or metastatic HER2-mutant non-small-cell lung cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate the efficacy and safety of zongertinib in untreated patients with advanced HER2-mutant non-small-cell lung cancer (NSCLC).

April 18, 2026New England Journal of Medicine11 citations

First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

View Full Paper

JHJohn V. Heymach NYNoboru Yamamoto NGNicolas Girard

Key Points

The aim is to evaluate the efficacy and safety of zongertinib in untreated patients with advanced HER2-mutant non-small-cell lung cancer (NSCLC).
Clinical trial design focusing on previously untreated patients
Assessment of treatment-related adverse events
Evaluation of drug efficacy over time
Zongertinib shows sustained efficacy in advanced or metastatic HER2-mutant NSCLC
Adverse events related to treatment were mostly low-grade

Abstract

Zongertinib showed sustained efficacy in previously untreated patients with advanced or metastatic HER2-mutant NSCLC. Treatment-related adverse events were predominantly low-grade. (Funded by Boehringer Ingelheim; Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804.).

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Heymach et al. (2026) studied this question.

synapsesocial.com/papers/69e31ec840886becb653e63b https://doi.org/10.1056/nejmoa2516969

Ask AI

Helpful

Bookmark

View Full Paper

April 18, 2026New England Journal of Medicine11 citations

First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

View Full Paper

JHJohn V. Heymach NYNoboru Yamamoto NGNicolas Girard

Key Points

The aim is to evaluate the efficacy and safety of zongertinib in untreated patients with advanced HER2-mutant non-small-cell lung cancer (NSCLC).
Clinical trial design focusing on previously untreated patients
Assessment of treatment-related adverse events
Evaluation of drug efficacy over time
Zongertinib shows sustained efficacy in advanced or metastatic HER2-mutant NSCLC
Adverse events related to treatment were mostly low-grade

Abstract

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Heymach et al. (2026) studied this question.

synapsesocial.com/papers/69e31ec840886becb653e63b https://doi.org/10.1056/nejmoa2516969

Ask AI

Helpful

Bookmark

View Full Paper